Drug-induced anemia

Article written and reviewed by Dr Luca Moretti

Drug-induced anemia is an acquired form of anemia that develops after exposure to one or more pharmacological agents capable of interfering, through different mechanisms, with red blood cell production, metabolism or survival. This condition, which is often underdiagnosed, represents one of the main iatrogenic hematologic complications, particularly among patients receiving chronic polypharmacy or intensive treatment in oncology, infectious diseases and internal medicine. The heterogeneity of the mechanisms involved, the wide range of potentially responsible drugs and the broad spectrum of clinical presentations make drug-induced anemia an increasingly relevant diagnostic and management challenge in clinical practice.

Drug-induced anemia is not a single disease but a heterogeneous group of clinical conditions that share an iatrogenic origin. Presentations range from minimally symptomatic forms detected only on laboratory testing to acute and potentially fatal events such as immune-mediated hemolytic crises or bone marrow aplasia. Prompt recognition of the pharmacological cause is crucial to prevent progression to systemic complications, optimize treatment and avoid irreversible injury.

In an era of population aging and increasingly common polypharmacy, drug-induced anemia has assumed a central role not only because of its frequency, but also because of its effects on quality of life, prognosis of the underlying disease and overall outcomes in vulnerable patients.

Mechanisms and types of drug-induced anemia

Understanding the complexity of drug-induced anemia requires examining the mechanisms through which medications can disrupt red blood cell homeostasis and the different clinical forms that result. Red blood cells are the final product of a tightly regulated physiological process involving proliferation of hematopoietic stem cells, hemoglobin synthesis, erythroid maturation and maintenance of cellular integrity in the peripheral circulation. Drug-induced interference at any of these levels may produce anemia, whose severity and reversibility depend on both the characteristics of the drug and individual susceptibility.

The pathogenetic mechanisms of drug-induced anemia can be divided into four broad categories that reflect the nature and site of pharmacological action:

1. Suppression of bone marrow erythropoiesis
Many drugs, especially cytotoxic agents such as alkylating chemotherapy drugs, antimetabolites, anthracyclines and platinum compounds, as well as some immunosuppressants such as azathioprine, methotrexate and mycophenolate, exert direct toxic effects on bone marrow stem cells. This leads to reduced erythroid proliferation and maturation, which may range from ineffective erythropoiesis to selective red cell aplasia or global pancytopenia, depending on cumulative dose, duration of treatment and individual susceptibility. In exceptional cases, toxic injury may be irreversible and associated with permanent bone marrow dysfunction.

2. Immune-mediated and non-immune-mediated hemolysis
Numerous drug classes may induce drug-dependent antibodies, which often activate complement and cause intravascular hemolysis, or drug-independent IgG autoantibodies, as in methyldopa-associated disease, which generally cause phagocyte-mediated extravascular hemolysis. Other drugs, independently of the immune system, cause intrinsic red blood cell membrane fragility or increased oxidative stress, triggering hemolysis especially in patients with enzyme deficiencies such as G6PD deficiency.

3. Interference with erythropoietic cofactors
Some drugs can cause megaloblastic, sideroblastic or iron-deficiency anemia by interfering with absorption or metabolism of vitamin B12, folate, vitamin B6 or iron. Documented examples include proton pump inhibitors and metformin in relation to vitamin B12, anticonvulsants and folate antagonists in relation to folate, and isoniazid in relation to vitamin B6. Chloramphenicol instead causes bone marrow toxicity rather than cofactor deficiency.

4. Iatrogenic blood loss
Some drugs, particularly NSAIDs, oral anticoagulants and antiplatelet agents, increase the risk of acute or chronic bleeding, especially from the gastrointestinal tract or after procedures, and may lead to iron-deficiency anemia. Corticosteroids can contribute to gastrointestinal bleeding risk, but their role must be interpreted according to dose, clinical setting and concomitant risk factors, especially coadministration with NSAIDs. Although this mechanism is less often labeled as a direct drug-induced anemia, it can make an important contribution, particularly in older patients or those receiving multiple medications.

Together, these pathogenetic mechanisms produce an extremely variable spectrum of iatrogenic anemia. In mild cases, injury is compensated by homeostatic mechanisms such as increased erythropoietin and increased red blood cell production, whereas in severe cases progressive loss of red blood cell mass impairs tissue oxygen delivery leading to multiorgan dysfunction, tissue ischemia and increased mortality. A detailed understanding of the mechanisms through which drugs can cause anemia is essential for establishing an appropriate diagnostic and therapeutic strategy and preventing recurrence in patients at risk.

Classification and epidemiology

Drug-induced anemia is not a single condition but comprises multiple clinical forms that can be classified according to the etiopathogenetic mechanism, the type of drug involved and the associated clinical manifestations. Distinguishing among these forms is not merely academic, because it directly guides diagnostic evaluation, monitoring and treatment.

From an etiopathogenetic perspective, four main categories of drug-induced anemia can be distinguished:

• Anemia due to erythropoietic suppression: secondary to direct or indirect bone marrow toxicity. This category includes anemia induced by cytotoxic chemotherapy, immunosuppressants, some antibiotics such as chloramphenicol and linezolid, and antiviral drugs, with presentations ranging from selective erythroblastopenia to global bone marrow aplasia.
• Hemolytic anemia: characterized by accelerated red blood cell destruction that may be immune-mediated, through drug-related autoantibodies or immune complexes, or non-immune-mediated, through oxidative injury or membrane damage. Frequently implicated drugs include high-dose penicillins, cephalosporins, methyldopa, dapsone, nitrofurantoin, sulfonamides and quinidine.
• Anemia due to cofactor deficiency or antagonism: includes deficiency of vitamin B12, folate, iron or vitamin B6 caused by malabsorption or pharmacological interference. Examples include proton pump inhibitors and metformin for vitamin B12, methotrexate and trimethoprim for folate, anticonvulsants affecting folate metabolism and isoniazid for vitamin B6.
• Anemia due to iatrogenic blood loss: mainly related to occult chronic or acute bleeding, particularly with NSAIDs, anticoagulants, antiplatelet agents or combinations of drugs that impair hemostasis. Corticosteroids may contribute to gastrointestinal risk in selected settings, particularly when additional risk factors are present.

These categories are not always mutually exclusive. In frail patients or those receiving multiple medications, several pathogenetic mechanisms may coexist and produce complex clinical presentations.

The clinical classification of drug-induced anemia also considers severity and speed of onset:

• Acute forms: abrupt onset, often related to immune-mediated hemolytic crises or acute toxicity, for example after starting a new medication or following overdose. These forms require prompt recognition and treatment to prevent severe complications.
• Chronic forms: insidious and progressive course, typical of cumulative toxicity, cofactor deficiency, occult bleeding or gradual bone marrow suppression. They may remain unrecognized for months and become apparent only during intercurrent illness or worsening of the underlying disease.

The frequency of drug-induced anemia varies widely according to the drug, mechanism, dose, duration of exposure and population. There is no reliable estimate assigning a single proportion of adult acquired anemia to medications. Risk is higher in patients exposed to myelotoxic drugs, those receiving polypharmacy, patients with cancer, hospitalized patients and those with comorbidities that increase hematologic vulnerability.

Some drugs are particularly well known for their hematotoxic potential and account for most documented cases:

• Antineoplastic agents and immunosuppressants: through direct cytotoxic effects on bone marrow
• Antibiotics such as chloramphenicol, linezolid, high-dose penicillins and cephalosporins
• NSAIDs, antiplatelet agents and anticoagulants: through increased bleeding risk
• Primaquine and tafenoquine, dapsone and nitrofurantoin: through risk of oxidative hemolysis, particularly relevant in people with G6PD deficiency; this risk should not be indiscriminately extended to all antimalarial drugs or sulfonamides.
• Anticonvulsants and antimetabolites: through interference with folate; isoniazid: through functional vitamin B6 deficiency and possible sideroblastic anemia

These data highlight the importance of a careful medical and medication history in every patient who develops anemia without an apparent cause.

In clinical practice, the frequency of drug-induced anemia tends to increase further during prolonged hospitalization, intensive care, treatment of hematologic and solid malignancies, and in populations with immune vulnerability. Early identification of at-risk groups and individualized treatment protocols are key elements in preventing this iatrogenic complication.

Clinical Manifestations

The clinical manifestations of drug-induced anemia are extremely heterogeneous and depend critically on the pathogenetic mechanism, speed of onset, degree of red blood cell reduction and the presence of comorbidities or baseline frailty. The presentation can range from asymptomatic laboratory abnormalities to acute and potentially fatal syndromes. In many cases, signs and symptoms overlap with those of the underlying disease or other ongoing treatments, making diagnosis particularly challenging.

In subacute or chronic forms, patients typically develop progressive weakness, easy fatigability, tachycardia, exertional dyspnea and skin and mucosal pallor. These symptoms, which may be subtle and overlooked in older or multimorbid patients, result from the progressive reduction in tissue oxygen delivery. More advanced cases may also include headache, dizziness, palpitations, orthostatic hypotension and, in patients with limited cardiac reserve, congestive heart failure or worsening of pre-existing arrhythmias.

In patients with acute anemia, for example from immune-mediated hemolysis, an oxidative crisis or sudden bleeding, the clinical picture may be dramatic, with sudden marked pallor, hypotension, severe tachycardia, oliguria, cold sweating and signs of organ hypoperfusion. Massive acute hemolysis may cause jaundice, dark urine from hemoglobinuria, low back pain and acute kidney injury related to free hemoglobin in the renal tubules.

Some pathogenetic mechanisms produce characteristic clinical patterns that can guide diagnostic suspicion:

• Immune-mediated hemolysis: fever, chills, low back pain, sudden jaundice, splenomegaly, hemoglobinuria and, in severe cases, shock and DIC (disseminated intravascular coagulation).
• Folate or vitamin B12 deficiency: subacute anemia associated with glossitis and gastrointestinal symptoms; paresthesias, sensory deficits and other neurologic manifestations point mainly to vitamin B12 deficiency, not isolated folate deficiency.
• Iatrogenic blood loss: progressive weakness, features of iron-deficiency anemia such as atrophic glossitis, brittle nails and angular stomatitis, occult blood in stool or overt bleeding.
• Direct bone marrow toxicity: signs of associated pancytopenia such as petechiae, ecchymoses and recurrent infections when several marrow lineages are affected, particularly after chemotherapy or exposure to myelotoxic drugs.

When interpreted in the appropriate clinical and pharmacological context, these findings make it possible to distinguish among the main forms of drug-induced anemia and rapidly guide the diagnostic workup.

The severity of clinical manifestations also depends on the speed of onset, the absolute hemoglobin concentration and the patient's hemodynamic compensation. Young healthy individuals may tolerate substantial reductions in hemoglobin with relatively few symptoms, whereas in older patients, people with heart disease or those with reduced hematopoietic reserve, even modest anemia may precipitate multiorgan decompensation.

In chronic forms, symptoms may remain unrecognized or be incorrectly attributed to other conditions, with a risk of progressive deterioration and late complications such as heart failure and overall functional decline. In patients with cancer, immunosuppression or intensive treatment, development of anemia may be a sign of drug toxicity and may require dose reduction, treatment interruption or modification of the therapeutic regimen.

In addition to specific clinical findings, drug-induced anemia may be associated with secondary complications such as:

• Increased infection risk when neutropenia or bone marrow aplasia is also present
• Coagulation-related manifestations, including petechiae and mucosal bleeding, when bone marrow toxicity causes thrombocytopenia
• Neurologic manifestations, particularly with vitamin B12 deficiency
• Kidney abnormalities secondary to acute hemolysis

These complications contribute to worsening prognosis, particularly in frail patients or those being treated for severe underlying disease.

In summary, the clinical picture of drug-induced anemia must be interpreted in close relation to the medication context, clinical history and current treatment. Prompt recognition of characteristic signs and symptoms is essential for early diagnosis and effective management.

Diagnostic Evaluation

Diagnosis of drug-induced anemia is a particularly challenging task in clinical practice because it requires integration of medical history, clinical findings and laboratory data to recognize a possible iatrogenic origin and identify the pathogenetic mechanism. The objective is not merely to confirm anemia, but to assess and, when possible, document the causal relationship with current pharmacological treatment, distinguish among the possible forms and determine the severity of associated complications.

Clinical suspicion often arises when an unexplained reduction in hemoglobin occurs in a patient receiving recent or chronic pharmacological treatment, particularly a drug known to have hematotoxic potential. Typical settings include hospitalized, older, oncologic or immunosuppressed patients and people with chronic diseases receiving multiple medications. Timing of symptom onset, the relationship with starting or modifying treatment, and the absence of other apparent causes of anemia such as bleeding, infection or nutritional deficiency are crucial elements for guiding diagnostic suspicion.

The first step in the diagnostic pathway is a complete blood count and morphological examination of the peripheral blood smear. The complete blood count documents reduced hemoglobin, hematocrit and red blood cell count and provides important information on other cell lines, including leukocytes and platelets, which can reveal pancytopenia. The peripheral blood smear makes it possible to identify characteristic morphological abnormalities:

• Morphologic findings that orient the mechanism: spherocytes in immune or extravascular hemolysis, schistocytes in mechanical or microangiopathic hemolysis, and bite or blister cells in oxidative forms
• Erythroblasts and immature cells in regenerative anemia
• Macro-ovalocytes, hypersegmented neutrophils and anisopoikilocytosis in megaloblastic anemia due to folate or vitamin B12 deficiency
• Hypochromia and microcytosis in anemia due to chronic bleeding or iron deficiency
• Pancytopenia on the complete blood count and, when examined, bone marrow hypocellularity in severe marrow toxicity

When interpreted in the clinical and pharmacological context, these findings may orient the specific form of drug-induced anemia.

The reticulocyte count provides another important clue: reticulocytosis indicates a regenerative bone marrow response, for example in acute hemolysis or bleeding, whereas reticulocytopenia suggests direct damage to erythroid progenitor cells, typical of anemia due to bone marrow toxicity or drugs that inhibit erythropoiesis.

Analysis of hemolysis markers, including indirect bilirubin, lactate dehydrogenase (LDH), haptoglobin and hemoglobinuria, is essential when drug-induced hemolytic anemia is suspected. Increased unconjugated bilirubin and LDH, reduced haptoglobin and free urinary hemoglobin indicate accelerated red blood cell destruction. A direct antiglobulin test may support an immune-mediated mechanism, but the result must be integrated with the clinical context and immunohematologic studies.

Assessment for cofactor deficiencies should be targeted according to the drug, expected mechanism, symptoms and risk factors. For example, in patients taking metformin, vitamin B12 testing is recommended when suggestive signs or symptoms are present, and periodic monitoring should be considered in people with risk factors; systematic measurement of vitamin B12, folate and iron in every exposed patient is not indicated. Testing relevant cofactors and, for iron, interpreting ferritin and transferrin saturation together with the clinical and inflammatory context can document deficiency, but does not by itself distinguish all other causes or mixed forms of anemia.

When anemia due to blood loss is suspected, investigations should be selected according to the likely site, symptoms, age and clinical risk. Fecal occult blood testing, gastrointestinal endoscopy or imaging are appropriate when there is a suitable suspicion of occult or overt bleeding. Use of anticoagulants, antiplatelet agents or NSAIDs increases suspicion but does not make these tests mandatory in every patient with anemia.

In patients with pancytopenia or suspected marrow toxicity, bone marrow examination by aspiration or biopsy may be indicated to assess cellularity, atypical elements or replacement of hematopoietic tissue. In selected cases, flow cytometry, cytogenetic studies and molecular testing may help exclude myelodysplastic syndromes, leukemia or other non-drug causes of bone marrow failure.

The differential diagnosis of drug-induced anemia includes many other forms of acquired anemia, such as primary nutritional deficiencies, occult bleeding unrelated to medications, hemoglobinopathies, chronic inflammatory diseases, infections and malignancies. Careful reconstruction of the clinical and medication timeline, supported by laboratory and instrumental investigations, makes it possible to assess the plausibility of an iatrogenic relationship and, when sufficient evidence is available, attribute the anemia to the responsible drug.

The rational sequence of diagnostic investigations can be summarized as follows:

• Careful collection of the medication and clinical history
• Complete blood count and peripheral smear with morphological analysis
• Reticulocyte count, bilirubin, LDH, haptoglobin and relevant vitamin and iron studies
• Direct antiglobulin test when immune-mediated hemolysis is suspected
• Targeted investigation of occult or overt bleeding, using fecal tests, endoscopy or imaging when indicated by the clinical context
• Bone marrow evaluation in refractory cytopenia or suspected aplasia

This logical pathway makes it possible to reach a precise diagnosis, promptly guiding withdrawal of the responsible drug and initiation of appropriate treatment.

Treatment and Prognosis

Management of drug-induced anemia requires an individualized approach based on prompt identification of the etiopathogenetic mechanism, specific management of the responsible medication, which may include withdrawal, modification or continuation with treatment of a deficiency, and treatment of complications. The goal is not only to correct anemia but also to prevent deterioration of the underlying condition, protect organ function and reduce the risk of recurrence or irreversible injury. Collaboration among the prescribing physician, hematologist and other specialists involved is essential for comprehensive and safe care.

Drug withdrawal and general strategies

Initial management depends on the mechanism and severity. In immune hemolysis or other clinically severe hematologic toxicities, the suspected drug should be stopped when the benefit-risk balance allows. In drug-induced deficiencies or when treatment is indispensable, it may instead be appropriate to correct the deficiency, reduce or modify the dose, or continue the drug with monitoring according to specific recommendations. If substitution is necessary, an appropriate alternative not associated with the same causal mechanism and with a more favorable hematologic profile should be selected, taking potential cross-reactivity into account. When withdrawal is not feasible, for example in some oncologic or transplant settings, careful benefit-risk assessment and dose individualization are essential, with close monitoring of hematologic parameters.
Early withdrawal of the drug is often sufficient for resolution of mild to moderate or subacute forms. Severe or acute forms instead require specialist management with supportive therapies or targeted interventions.

Transfusion support

In cases of severe anemia with signs of tissue hypoxia, hemodynamic compromise or immediate threat to life, compatible packed red blood cells may be transfused according to standard hematologic protocols. Transfusion should generally follow a restrictive strategy that integrates hemoglobin concentration, symptoms, hemodynamic stability, comorbidities and clinical context. In hemodynamically stable hospitalized adults, transfusion may be considered when Hb is <7 g/dL, together with investigation and correction of reversible causes and specific management of the responsible medication, which may require withdrawal, modification or continuation with treatment of the deficiency according to mechanism and benefit-risk balance. Acute myocardial infarction is an exception: in hospitalized patients with acute myocardial infarction, the 2025 AABB guideline suggests a liberal transfusion strategy when Hb is <10 g/dL, with a conditional recommendation and low certainty of evidence.
Monitoring for transfusion reactions, iron balance and possible complications such as alloimmunization and transfusion-transmitted infections is essential, particularly in patients requiring repeated or prolonged transfusion support.

Treatment of immune-mediated forms

Drug-induced immune-mediated hemolytic anemia first requires immediate withdrawal of the causative agent and supportive care, including compatible transfusion when necessary. Corticosteroids are not a universal first-line treatment; they may be considered mainly in forms with drug-independent autoantibodies or selected severe presentations. Immunoglobulin, rituximab or plasma exchange have exceptional indications depending on mechanism and severity.

Management of cofactor-deficiency forms

When anemia is caused by drug-induced deficiency of vitamin B12, folate or iron, replacement therapy is indicated orally or, in cases of malabsorption or intestinal disease, parenterally. Treatment should continue for the time needed to restore tissue stores and, if the implicated drug is indispensable, long-term supplementation under close hematologic monitoring may be necessary.

Management of bone marrow toxicity

Bone marrow toxicity caused by cytotoxic drugs, antibiotics or immunosuppressants requires withdrawal of the causative drug when possible and supportive care based on the type and severity of cytopenias. In severe aplastic anemia, erythropoietin and G-CSF are not routine treatment for marrow failure. Specialist management includes transfusion support, prevention and treatment of infections, and specific treatment such as immunosuppression or hematopoietic stem cell transplantation in eligible patients.

Management of iatrogenic blood loss

In anemia caused by drug-associated bleeding from NSAIDs, anticoagulants or antiplatelet agents, interruption of the bleeding-promoting drug should be individualized according to bleeding severity, the indication for treatment and thrombotic risk. Management also includes correction of any underlying coagulopathy, targeted transfusion support and, in selected cases, endoscopy or surgery to control bleeding.

Prevention and monitoring

Prevention of drug-induced anemia is based on careful assessment of individual risk factors such as age, comorbidities, enzyme or genetic deficiencies and nutritional status, individualized treatment protocols and selection of drugs with lower hematologic toxicity in at-risk patients. Periodic monitoring of the complete blood count and hematologic indices during potentially high-risk therapies is essential for early recognition of anemia and prompt adjustment of treatment.

Prognosis

The prognosis of drug-induced anemia depends on the mechanism and severity. Mild to moderate or subacute forms are often favorable when the problem is recognized promptly and managed with the appropriate specific strategy, which may include drug withdrawal or modification, replacement treatment for a deficiency and monitoring. In acute, severe or immune-mediated forms, or when major comorbidities are present, morbidity and mortality increase substantially and rapid specialist intervention with multidisciplinary follow-up is required.

• Prompt diagnosis and withdrawal of the causative drug
• Management of complications and comorbidities
• Individualization of treatment protocols
• Patient education to recognize warning symptoms

Prevention remains the most effective strategy. Thoughtful drug selection, continuous surveillance and awareness among healthcare professionals are key tools for reducing the incidence and impact of iatrogenic anemia in clinical practice.

Future advances, through the identification of genetic susceptibility markers, development of less toxic drugs and increasingly refined monitoring protocols may further reduce the risk of iatrogenic anemia and improve quality of life for patients receiving chronic or complex pharmacological treatment.

Complications

The complications of drug-induced anemia are one of the main sources of morbidity in patients receiving prolonged treatment or drugs with substantial hematotoxic potential. They result from the direct effects of reduced hemoglobin, from the underlying pathogenetic mechanisms such as hemolysis, bone marrow aplasia, cofactor deficiency or blood loss, and from therapies used to correct anemia and treat the underlying disease.

Complications of chronic anemia

Persistent anemia that is not adequately managed is associated with increased risk of:

• Heart failure and myocardial ischemia in patients with limited cardiac reserve
• Global functional decline, worsening frailty and reduced independence
• Neurocognitive symptoms, confusion and psychomotor slowing, particularly in older adults
• Delayed wound healing and worsening prognosis of concomitant diseases

These complications may adversely affect quality of life and increase mortality, especially in frail patients or those with chronic disease.

Complications of acute or chronic hemolysis

Iatrogenic hemolytic anemia is often associated with:

• Jaundice and indirect hyperbilirubinemia
• Hemoglobinuria and risk of acute kidney injury related to free hemoglobin
• Massive intravascular hemolysis with possible hyperkalemia, acute kidney injury and hemodynamic instability
• Splenomegaly and, in chronic forms, possible hypersplenism

Severe immune-mediated forms may lead to hemolytic shock, DIC (disseminated intravascular coagulation) and multiorgan complications.

Infectious and immunologic complications

Immunosuppressive treatment or drug-induced bone marrow toxicity can predispose to:

• Opportunistic bacterial, viral and fungal infections, including severe infections
• Persistent fever and sepsis in patients with neutropenia
• Allergic or autoimmune reactions during treatment with biologic or immunomodulatory drugs

Infection risk increases with pancytopenia, corticosteroid or chemotherapy exposure and in older or immunocompromised patients.

Bleeding complications

In patients treated with anticoagulants, antiplatelet agents or NSAIDs, or in those with bone marrow toxicity, the main complications include:

• Gastrointestinal bleeding such as melena, hematemesis or hematochezia
• Mucosal bleeding involving the gums, nose, urinary tract or uterus
• Petechiae, widespread ecchymoses and spontaneous bleeding in severe thrombocytopenia

These complications often require urgent intervention to control bleeding and correct hemostatic abnormalities.

Complications of transfusion and immunosuppressive therapy

Repeated transfusions and immunosuppressive therapy carry specific risks, including:

• Alloimmunization, with development of red blood cell antibodies that can complicate subsequent transfusions
• Acute and delayed transfusion reactions, including fever, chills and hemolytic reactions
• Transfusion-transmitted infections such as HCV, HBV, HIV and parvovirus B19
• Iron overload in patients requiring frequent transfusions
• Toxicity from corticosteroids and immunosuppressants, including diabetes, osteoporosis and increased risk of serious infection

These complications require ongoing monitoring and targeted prevention, with individualized transfusion and immunosuppressive strategies.

Rare and long-term complications

Some patients may develop late or uncommon complications, including:

• Neurologic abnormalities, such as cognitive impairment associated with chronic anemia or vitamin B12 deficiency
• Endocrine disorders, such as hypogonadism or thyroid dysfunction
• Psychosocial complications, including depression, anxiety, impaired quality of life and reduced treatment adherence

These issues are particularly relevant in patients receiving prolonged treatment or multidrug chemotherapy, in whom multidisciplinary surveillance and psychological support are key components of care.

In summary, complications of drug-induced anemia are often multifactorial, interdependent and potentially severe. Early recognition, active prevention and integrated management are essential to reduce morbidity, improve prognosis and optimize quality of life for patients receiving chronic or complex pharmacological treatment.

Bibliography
1. Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2009;2009:73–79.
2. Zaninoni A, Fattizzo B, Barcellini W. Current and emerging treatment options for autoimmune hemolytic anemia. Expert Rev Clin Immunol. 2018;14(10):857–872.
3. Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol. 2017;177(2):208–220.
4. Luzzatto L, Ally M, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Blood. 2020;136(11):1225–1240.
5. Youngster I, Arcavi L, Schechmaster R, et al. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf. 2010;33(9):713–726.
6. Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood. 2015;125(4):616-618.
7. Kulasekararaj A, Cavenagh J, Dokal I, et al. Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline. Br J Haematol. 2024;204(3):784-804.
8. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509-2519.
9. Devalia V, Hamilton MS, Molloy AM. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol. 2014;166(4):496–513.
10. Muñoz M, Acheson AG, Auerbach M, et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia. 2017;72(2):233-247.
11. Pagano MB, Stanworth SJ, Dennis J, et al. Red Cell Transfusion in Acute Myocardial Infarction: AABB International Clinical Practice Guidelines. Ann Intern Med. 2025;178(10):1469–1477. doi:10.7326/ANNALS-25-00706.